secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anixa Biosciences Inc (ANIX)
CIK:        0000715446
Form:       8-K
Filed at:   2022-12-08T23:59:59+00:00
Accession:  0001493152-22-034828
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anixa Biosciences reaches maximum tolerated dose in Phase 1a trial of breast cancer vaccine
--------------------------------------------------------------------------------

- Maximum tolerated dose achieved in Phase 1a trial of preventative breast cancer vaccine.
- Vaccine developed in collaboration with Cleveland Clinic.
- Results presented at San Antonio Breast Cancer Symposium; press release and poster furnished.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/715446/000149315222034828/0001493152-22-034828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/715446/000149315222034828/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-034828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer